You are here

blood cancer

FDA to delay decision on Bristol Myers-2seventy bio cancer therapy

FDA to delay decision on Bristol Myers-2seventy bio cancer therapy

Reuters

Bristol Myers Squibb

Flag link:

Bristol Myers pays $100M for a different kind of ADC

Bristol Myers pays $100M for a different kind of ADC

BioPharma Dive

Bristol Myers Squibb

antibody-drug conjugate

Orum Therapeutics

Flag link:

ALX follows Gilead in axing CD47 blood cancer trials as data disappoint

ALX follows Gilead in axing CD47 blood cancer trials as data disappoint

Fierce Biotech

Gilead Sciences

clinical trials

Flag link:

Amgen granted full FDA approval for blood cancer treatment

Amgen granted full FDA approval for blood cancer treatment

Biopharma Reporter

Flag link:

Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug

Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug

BioPharma Dive

relapsed or refractory diffuse large B-cell lymphoma

Flag link:

FDA delays approval decision on GSK's $1.9B blood cancer bet

FDA delays approval decision on GSK's $1.9B blood cancer bet

Fierce Biotech

Flag link:

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up

Fierce Pharma

Flag link:

Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug

Foghorn finally has clear route back to clinic after FDA lifts yearlong hold on blood cancer drug

Fierce Biotech

Foghorn Therapeutics

Flag link:

Allogeneic cell therapy approval to pave the way for future therapies in this class

Allogeneic cell therapy approval to pave the way for future therapies in this class

Clinical Trials Arena

stem cell transplant

Flag link:

FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market

FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market

Fierce Biotech

Flag link:

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE

Fierce Pharma

Gilead Sciences

Flag link:

With new data, Nkarta builds case for ‘natural killer’ cell therapy

With new data, Nkarta builds case for ‘natural killer’ cell therapy

BioPharma Dive

Nkarta Therapeutics

natural killer cell therapies

Flag link:

Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule

Jazz plays coda to blood cancer approval, securing FDA nod for revised dosing schedule

Fierce Pharma

Jazz Pharmaceuticals

acute lymphoblastic leukemia

lymphoblastic lymphoma

Flag link:

GSK to pull blood cancer drug from US market after study failure

GSK to pull blood cancer drug from US market after study failure

BioPharma Dive

clinical trials

Multiple Myeloma

Flag link:

Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis

Merck & Co. inks $1.4B blood cancer biotech buyout to muscle in on Bristol Myers, Novartis

Fierce Biotech

Imago BioSciences

Flag link:

After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024

After chat with FDA, ImmunoGen delays pivotal top-line data on blood cancer ADC to 2024

Fierce Biotech

antibody drug conjugate

pivekimab sunirine

Flag link:

Novartis suspends platform trial, advancement shot of four blood cancer assets drop

Novartis suspends platform trial, advancement shot of four blood cancer assets drop

Clinical Trials Arena

clinical trials

uterine leiomyoma

Flag link:

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

Fierce Biotech

Flag link:

ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio

ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio

Endpoints

bispecific antibodies

Flag link:

Mei, with Bayer and Gilead in its sights, posts pivotal data on blood cancer prospect

Mei, with Bayer and Gilead in its sights, posts pivotal data on blood cancer prospect

Fierce Biotech

follicular lymphoma

Gilead Sciences

Flag link:

Pages